| Literature DB >> 26617891 |
Chao Chen1, Haiqing Hua1, Chenglong Han1, Yuan Cheng1, Yin Cheng1, Zhen Wang1, Jutao Bao1.
Abstract
The role of MGMT promoter methylation in lung cancer (LC) remains controversial. To clarify the association of MGMT promoter methylation with survival in LC, we performed a meta-analysis of the literature with meta-analysis. Trials were selected for further analysis if they provided an independent assessment of MGMT promoter methylation in LC and reported the survival data in the context of MGMT promoter methylation status. Subgroup analyses were conducted according to the study characteristic. A total of 9 trials, which comprised 859 patients, were included in the meta-analysis. The combined hazard ratio (HR) of 1.27 [95% CI 0.88-1.82; test for heterogeneity P = 0.027] suggests that MGMT promoter methylation has none impact on patient survival. In Stage I-III or younger populations, a significant association was found for MGMT promoter methylation in the prognosis of LC. In addition, the heterogeneity disappeared when the analysis was restricted to Stage I-III LC. Our analysis indicates that MGMT promoter methylation in stage I-III or younger patients was significantly correlated with wore survival. Further study is needed to determine these specific subgroups of LC patients.Entities:
Keywords: MGMT; lung cancer; meta-analysis; methylation; prognosis
Mesh：
Substances：
Year: 2015 PMID： 26617891 PMCID： PMC4637707
Source DB: PubMed Journal: Int J Clin Exp Pathol ISSN： 1936-2625